Our group studies cancer heterogeneity at the genetic and cell state level. From a genetics perspective, we focus on understanding large-scale chromosomal changes known as copy number alterations (CNAs). We combine state-of-the-art genome engineering strategies to uncover the mechanisms by which CNAs enable cancer cells to disseminate and resist therapies.

We are particularly interested in the role of these alterations in immune surveillance, tumor heterogeneity, and cancer genome evolution. We also leverage our genome engineering expertise to devise novel strategies to image, trace, and dissect the function of complex cell states in cancer. We aim to understand how genetic and phenotypic heterogeneity drives cancer progression and therapy resistance. Our ultimate goal is to identify the underlying principles that govern cancer heterogeneity and use this knowledge to design new therapeutic strategies that control cancer and improve patient care.